← Search & browse all drugs
NERVOUS SYSTEM › OTHER NERVOUS SYSTEM DRUGS › PARASYMPATHOMIMETICS › Other parasympathomimetics
cevimeline
N07AX03
Adult Dosing
- 30 mg orally three times daily
Pediatric Dosing
- Safety and efficacy in pediatric patients have not been established
Indications
- Treatment of symptoms of dry mouth in patients with Sjögren's syndrome
Mechanism of Action
- Cholinergic agonist that binds to muscarinic (M1 and M3) receptors, stimulating secretion of exocrine glands such as salivary and lacrimal glands
Contraindications
- Uncontrolled asthma
- Known hypersensitivity to cevimeline
- Conditions where miosis is undesirable (e.g., acute iritis, narrow-angle glaucoma)
Adverse Reactions
- Excessive sweating (diaphoresis)
- Nausea
- Rhinitis
- Sinusitis
- Upper respiratory tract infection
- Diarrhea
- Excessive salivation
- Urinary frequency
- Visual disturbance
Drug Interactions
- Beta-adrenergic blockers may increase risk of conduction disturbances
- CYP3A4 inhibitors (e.g., ketoconazole, erythromycin) may increase cevimeline plasma concentrations
- CYP2D6 inhibitors (e.g., paroxetine, quinidine) may increase cevimeline plasma concentrations
- Drugs with parasympathomimetic effects may cause additive toxicity
Curated Content: Needs Vetting Before Put to Clinical Use